Results 131 to 140 of about 74,225 (263)

Chitosan nanoparticle‐mediated delivery of anti‐miR‐203a‐3p for 4T1 triple‐negative breast cancer

Indonesian Journal of Biotechnology
Anti‐miR molecules can suppress specific microRNA (miRNA) functions within critical signaling pathways. Chitosan acts as a delivery system for miRNAs; therefore, encapsulating miR‐203a‐3p is essential for targeted delivery and biological activity.
Jecklyn Shindy Temartenan, Hairil Fiqri, Pamungkas Bagus Satriyo, Sofia Mubarika Haryana   +3 more
doaj   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Innovation of plant‐derived extracellular vesicles and interdisciplinary research: From discovery to biomedical applications

BMEMat, EarlyView.
Plant‐derived extracellular vesicles offer numerous advantages and are regarded as highly promising candidates in the field of biomedicine. Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells.
Zilin Li, Yi Wei, Ben Hu, Yafang Song, Xiaojia Chen, Nik Ahmad Nizam Nik Malek, Tongkai Chen   +6 more
wiley   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion

Exploration, EarlyView.
Over the past decades, chimeric antigen receptor (CAR)‐T cell therapy has evolved from a linear engineering concept into a powerful yet constrained immunotherapy, limited by tumour microenvironment barriers, immune evasion, and manufacturing complexity.
Yuesong Bai, Jintao Qin, Zongjun Dai, Ran Yan, Yong Yang, Wenguang Wang   +5 more
wiley   +1 more source

DataSheet_1_Antineoplastic effect of compounds C14 and P8 on TNBC and radioresistant TNBC cells by stabilizing the K-Ras4BG13D/PDE6δ complex.docx

IntroductionBreast cancer (BC) is the leading cause of cancer-related deaths among women, with triple-negative breast cancer (TNBC) representing one of the most aggressive and treatment-resistant subtypes.
Paola Briseño-Díaz (6164663), Marco Antonio Meraz-Ríos (8124149), María del Rocío Thompson-Bonilla (3342392), Dayan A. Carrión-Estrada (18187744), Mayra Montecillo-Aguado (11955098), Martiniano Bello (152281), Elena Arechaga-Ocampo (415611), Miguel Vargas (85521), Rosaura Hernández-Rivas (510505), Arturo Aguilar-Rojas (18187747), Arturo Rojo-Domínguez (5919902), Sara Huerta-Yepez (743626)   +11 more
core   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues [PDF]

, 2018
浜松医科大学博士（医学）doctoral医学系研究科Triple-negative breast cancer (TNBC) is one of the breast cancer subtype that displays a high risk of early recurrence and short overall survival.
細川, 優子
core  

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source

Differentiation of triple-negative breast cancer and benign breast lesions using multiparametric ultrasonography

Journal of Ultrasonography
Assessment of features of triple-negative breast cancer (TNBC) and benign breast lesions in multipara-metric ultrasonography, with an emphasis on the added value of sonoelastography.
Gumowska Magdalena, Dobruch-Sobczak Katarzyna Sylwia   +1 more
doaj   +1 more source